Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a
follow up period of 12 months. The purpose of the study is to assess the safety and efficacy
of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients
with chronic kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
Ditte Hansen
Collaborators:
Odense University Hospital Rigshospitalet, Denmark Steno Diabetes Center Copenhagen Universiteit Antwerpen